CT-Based Radiomics Can Predict the Efficacy of Anlotinib in Advanced Non-Small-Cell Lung Cancer

Figure 5

Kaplan–Meier survival analyses of PFS between the low- and high-risk groups in the CE-CT cohort based on the RAD score only and a combination of radiomics and clinical features, respectively. (a) The CE radiomic only model in the internal validation set; (b) the CE radiomic only model in the external validation set; (c) the CE radiomics-combined model in the internal validation set; (d) the CE radiomic-combined model in the external validation set.

(a)

(b)

(c)

(d)